Short answer
Journey Medical Corp (DERM) filed its Q2 2026 10-Q quarterly report on Aug 12, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $18M (up 18.9% year over year) with net income of −$312,000.
Q2 2026 key financials · XBRL
- Revenue
- $18M
- +18.9% YoY · +12.0% QoQ
- Net income
- −$312,000
- +91.8% YoY · +86.0% QoQ
- Operating margin
- 2.6%
- EPS (diluted)
- −$0.01
- +93.8% YoY · +87.5% QoQ
Source: XBRL data from the Journey Medical Corp (DERM) Q2 2026 10-Q on SEC EDGAR. USD.
Journey Medical Corp Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $18.5M, up 23% YoY from $15.0M
- Emrosi revenue $8.1M, up 189% YoY; Qbrexza lowest performer, down 26% to $5.1M
- Operating income $0.5M vs $2.9M loss YoY; operating margin 2.5% vs (19.2)%
- Cash $25.6M vs $24.1M at December 31, 2025; six-month operating cash flow $1.2M vs $(3.8)M
- Going-concern substantial doubt; potential debt or equity financing and generic competition cited as headwinds
Risk Factors
- No material changes disclosed from 2025 Form 10-K risk factors
- Additional unknown risks could materially adversely affect business, financial condition, or results
- No unregistered equity sales during the quarter
- No defaults upon senior securities reported
- No director or officer Rule 10b5-1 trading-plan activity during the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Journey Medical Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.